file
timezone icon TimeZone (UTC)
FDA Grand Rounds, "Science to Inform a Nicotine Product Standard," presented by Lynn C. Hull, PhD, CTP, 10/11/2018, 12-1pm EST
Thursday, October 11, 2018 3:45:00 PM UTC - 6:15:00 PM UTC
See here: www.FDA.gov/GrandRounds

This presentation will give an overview of the systematic literature review that FDA’s Center for Tobacco Products has done on the likely effects of reducing nicotine in combusted tobacco, as well as on consumer knowledge, attitudes, perceptions, beliefs, and planned behavior on reduced nicotine tobacco products.

Use of combusted tobacco products like cigarettes, kreteks, bidis, cigarette tobacco, roll-your-own tobacco, cigars, pipe tobacco, and water pipe tobacco causes a heavy burden of death and disease every year. These negative health effects are ultimately the result of users’ addiction to the nicotine in tobacco products, which in turn results in their repeated use. This continuously exposes users and non-users (via second- or third-hand smoke) to toxicants in the smoke.

FDA has issued an Advanced Notice of Proposed Rulemaking for a product standard to set a maximum nicotine level in cigarettes. FDA continues to assess the best available science to determine a level at which these products would be minimally addictive and, therefore, appropriate for protecting the public health.

FDA’s Center for Tobacco Products has suggested that extended exposure to combusted cigarettes containing tobacco filler in the 0.02 - 0.07 mg nicotine content per cigarette range (i.e., very low nicotine content) could be associated with reduced addiction potential, dependence levels, the number of cigarettes smoked per day, and increased quit rates among current smokers, without evidence of increased toxicant exposure, craving, withdrawal, or compensatory smoking.

The reviewed literature also indicates that, although a substantial portion of adult American consumers understand that nicotine is the addictive chemical in cigarettes, a substantial number of adults also incorrectly believe that nicotine is carcinogenic and a main cause of smoking-related disease. Therefore, increased efforts to communicate the science behind a nicotine product standard will be needed to educate the public before any implementation of a nicotine product standard.

Speaker

Lynn C. Hull, PhD, CTP
Lynn Hull, PhD
Lead Pharmacologist
Division of Individual Health Science
FDA’s Center for Tobacco Products

If you've never used Adobe Connect, get a quick overview: http://www.adobe.com/products/adobeconnect.html
Adobe, the Adobe logo, Acrobat and Adobe Connect are either registered trademarks or trademarks
of Adobe Systems Incorporated in the United States and/or other countries.